Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of Ilaris canakinumab when used in patients with Schnitzlers syndrome. It focuses on patients who are using canakinumab for the first time to treat this condition, assessing clinical responses and monitoring various health markers over time. Participants will be observed while receiving canakinumab as part of their clinical care for Schnitzlers syndrome. The study includes monitoring clinical responses from 7 days up to 48 weeks after the first dose, with assessments at multiple time points including day 8 and every 8 weeks thereafter. This observational approach registers patients starting treatment before and after study enrollment. Throughout the study, participants undergo regular evaluations including clinical response assessments, physician global impressions, and laboratory tests measuring white blood cells, neutrophils, C-reactive protein, alkaline phosphatase, and immunoglobulin levels. Safety is closely monitored by recording any adverse reactions or serious events up to 48 weeks. The total participation duration aligns with the follow-up period of up to 48 weeks to track treatment outcomes and safety.